Akèy › Limfom selil mantèl › Minnesota
Etid klinik pou Limfom selil mantèl nan Minnesota
14 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- ak 13 plis
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05976763A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Jun 25, 2026 · NCT03314974Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Feb 27, 2026 · NCT06151730BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT06854003BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- University of Minnesota, Minneapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT05370430Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Nov 4, 2025 · NCT03125642SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 18, 2024 · NCT05910801Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.